Current lynch syndrome tumor screening practices: A survey of genetic counselors

Journal of Genetic Counseling

Volumn 23, Issue 1, 2014, Pages 38-47

  Cohen, Stephanie A ^a  

^a ST VINCENT HOSPITAL   (United States)

Author keywords

Cancer genetic counseling; Immunohistochemistry; Lynch syndrome; Microsatellite instability; Universal screening

Indexed keywords

ARTICLE; ENDOMETRIUM TUMOR; FEMALE; GENETIC COUNSELING; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; MALE; METHODOLOGY; MICROSATELLITE INSTABILITY;

COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; ENDOMETRIAL NEOPLASMS; FEMALE; GENETIC COUNSELING; HUMANS; MALE; MICROSATELLITE INSTABILITY;

EID: 84897605070     PISSN: 10597700     EISSN: 15733599     Source Type: Journal    
DOI: 10.1007/s10897-013-9603-5     Document Type: Review

References (60)

1. Backes, F. J.; Mitchell, E.; Hampel, H.; & Cohn, D. E. (2011). Endometrial cancer patients and compliance with genetic counseling: room for improvement. Gynecologic Oncology. doi: 10.1016/j.ygyno.2011.09.002.
2. Baglietto, L.; Lindor, N. M.; Dowty, J. G.; White, D. M.; Wagner, A.; Gomez Garcia, E. B.; et al. (2010). Risks of lynch syndrome cancers for MSH6 mutation carriers. Journal of the National Cancer Institute, 102(3), 193-201. doi: 10.1093/jnci/djp473.
3. Barnetson, R. A.; Tenesa, A.; Farrington, S. M.; Nicholl, I. D.; Cetnarskyj, R.; Porteous, M. E.; et al. (2006). Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. The New England Journal of Medicine, 354(26), 2751-2763. doi: 10.1056/NEJMoa053493.
4. Barrow, E.; Alduaij, W.; Robinson, L.; Shenton, A.; Clancy, T.; Lalloo, F.; et al. (2008). Colorectal cancer in HNPCC: cumulative lifetime incidence, survival and tumour distribution. A report of 121 families with proven mutations. Clinical Genetics, 74(3), 233-242. doi: 10.1111/j.1399-0004.2008. 01035.x.
5. Barrow, E.; Robinson, L.; Alduaij, W.; Shenton, A.; Clancy, T.; Lalloo, F.; et al. (2009). Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations. Clinical Genetics, 75(2), 141-149. doi: 10.1111/j.1399-0004.2008.01125.x.
6. Beamer, L.; Grant, M.; Espenschied, C.; Blazer, K.; Hampel, H.; Weitzel, J.; et al. (2012). Reflex immunohistochemistry and microsatellite instability testing of colorectal tumors for Lynch syndrome among US cancer programs and follow-up of abnormal results. Journal of Clinical Oncology, 30(10), 1058-1063.
7. Bellcross, C. A.; Bedrosian, S. R.; Daniels, E.; Duquette, D.; Hampel, H.; Jasperson, K.; et al. (2012). Implementing screening for Lynch syndrome among patients with newly diagnosed colorectal cancer: summary of a public health/clinical collaborative meeting. Genetics in Medicine, 14(1), 152-162.
8. Bellizzi, A. M.; & Frankel, W. L. (2009). Colorectal cancer due to deficiency in DNA mismatch repair function: a review. Advances in Anatomic Pathology, 16(6), 405-417. doi: 10.1097/PAP.0b013e3181bb6bdc.
9. Bouzourene, H.; Hutter, P.; Losi, L.; Martin, P.; & Benhattar, J. (2010). Selection of patients with germline MLH1 mutated Lynch syndrome by determination of MLH1 methylation and BRAF mutation. Familial Cancer, 9(2), 167-172. doi: 10.1007/s10689-009-9302-4.
10. Burks, R. T.; Kessis, T. D.; Cho, K. R.; & Hedrick, L. (1994). Microsatellite instability in endometrial carcinoma. Oncogene, 9(4), 1163-1166.
11. Burt, R. W.; Giardiello, F. M.; Jasperson, K.; Lynch, P. M.; Steinbach, G. (2011). NCCN Guidelines v.2.2011 Colorectal Cancer Screening. www.nccn.org. Accessed 3-1-2012 2012.
12. Byfield, S. A.; & Syngal, S. (2008). Clinical guidelines versus universal molecular testing: are we ready to choose an optimal strategy for Lynch syndrome identification? American Journal of Gastroenterology, 103(11), 2837-2840. doi: 10.1111/j.1572-0241.2008.02091.x.
13. Chubak, B.; Heald, B.; & Sharp, R. R. (2011). Informed consent to microsatellite instability and immunohistochemistry screening for Lynch syndrome. Genetics in Medicine, 13(4), 356-360. doi: 10.1097/GIM. 0b013e31820aee09.
14. Cunningham, J. M.; Christensen, E. R.; Tester, D. J.; Kim, C.-Y.; Roche, P. C.; Burgart, L. J.; et al. (1998). Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Research, 58(15), 3455-3460.
15. Des Guetz, G.; Schischmanoff, O.; Nicolas, P.; Perret, G.-Y.; Morere, J.-F.; & Uzzan, B. (2009). Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis. European Journal of Cancer, 45(10), 1890-1896. doi: 10.1016/j.ejca.2009.04.018.
16. Dove-Edwin, I.; Sasieni, P.; Adams, J.; & Thomas, H. J. (2005). Prevention of colorectal cancer by colonoscopic surveillance in individuals with a family history of colorectal cancer: 16 year, prospective, follow-up study. BMJ, 331(7524), 1047. doi: 10.1136/bmj.38606.794560.EB.
17. EGAPP. (2009). Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genetics in Medicine, 11(1), 35-41.
18. Evans, D. G.; Walsh, S.; Hill, J.; & McMahon, R. T. (2007). Strategies for identifying hereditary nonpolyposis colon cancer. Seminars in Oncology, 34(5), 411-417. doi: 10.1053/j.seminoncol.2007.07.001.
19. Fitzgibbons, R. J.; Jr.; Lynch, H. T.; Stanislav, G. V.; Watson, P. A.; Lanspa, S. J.; Marcus, J. N.; et al. (1987). Recognition and treatment of patients with hereditary nonpolyposis colon cancer (Lynch syndromes I and II). Annals of Surgery, 206(3), 289-295.
20. Garg, K.; & Soslow, R. A. (2009). Lynch syndrome (hereditary non-polyposis colorectal cancer) and endometrial carcinoma. Journal of Clinical Pathology, 62(8), 679-684. doi: 10.1136/jcp.2009.064949.
21. Gudgeon, J.; Williams, J.; Burt, R. W.; Samowitz, W.; Snow, G.; & Williams, M. (2011). Lynch syndrome screening implementation: business analysis by a healthcare system. The American Journal of Managed Care, 17(8), e288-e300.
22. Hall, M. J. (2010). Counterpoint: implementing population genetic screening for lynch syndrome among newly diagnosed colorectal cancer patients - will the ends justify the means? Journal of the National Comprehensive Cancer Network, 8(5), 606-611.
23. Hampel, H. (2010). Point: justification for lynch syndrome screening among all patients with newly diagnosed colorectal cancer. Journal of the National Comprehensive Cancer Network, 8(5), 597-601.
24. Hampel, H.; Frankel, W. L.; Martin, E.; Arnold, M.; Khanduja, K.; Kuebler, P.; et al. (2005a). Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). The New England Journal of Medicine, 352(18), 1851-1860. doi: 10.1056/NEJMoa043146.
25. Hampel, H.; Stephens, J. A.; Pukkala, E.; Sankila, R.; Aaltonen, L. A.; Mecklin, J.-P.; et al. (2005b). Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later Age of onset. Gastroenterology, 129(2), 415-421. doi: 10.1053/j.gastro.2005.05.011.
26. Hampel, H.; Frankel, W.; Panescu, J.; Lockman, J.; Sotamaa, K.; Fix, D.; et al. (2006). Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Research, 66(15), 7810-7817. doi: 10.1158/0008-5472.CAN-06-1114.
27. Hampel, H.; Frankel, W. L.; Martin, E.; Arnold, M.; Khanduja, K.; Kuebler, P.; et al. (2008). Feasibility of screening for Lynch syndrome among patients with colorectal cancer. Journal of Clinical Oncology, 26(35), 5783-5788. doi: 10.1200/JCO.2008.17.5950.
28. Herman, J. G.; Umar, A.; Polyak, K.; Graff, J. R.; Ahuja, N.; Issa, J.-P. J.; et al. (1998). Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proceedings of the National Academy of Sciences, 95(12), 6870-6875.
29. Jarvinen, H. J.; Renkonen-Sinisalo, L.; Aktan-Collan, K.; Peltomaki, P.; Aaltonen, L. A.; & Mecklin, J. P. (2009). Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members. Journal of Clinical Oncology, 27(28), 4793-4797. doi: 10.1200/JCO.2009.23.7784.
30. Karlan, B. Y.; Berchuck, A.; & Mutch, D. (2007). The role of genetic testing for cancer susceptibility in gynecologic practice. Obstetrics and Gynecology, 110(1), 155-167. doi: 10.1097/1001.AOG.0000269050.0000279143. 0000269084.
31. Kwon, J. S.; Scott, J. L.; Gilks, C. B.; Daniels, M. S.; Sun, C. C.; & Lu, K. H. (2011). Testing women with endometrial cancer to detect lynch syndrome. Journal of Clinical Oncology, 29(16), 2247-2252. doi: 10.1200/jco.2010.32.9979.
32. Ladabaum, U.; Wang, G.; Terdiman, J.; Blanco, A.; Kuppermann, M.; Boland, C. R.; et al. (2011). Strategies to identify the Lynch syndrome among patients with colorectal cancer. Annals of Internal Medicine, 155(2), 69-79. doi: 10.1059/0003-4819-155-2-201107190-00002.
33. Leenen, C. H. M.; van Lier, M. G. F.; van Doorn, H. C.; van Leerdam, M. E.; Kooi, S. G.; de Waard, J.; et al. (2012). Prospective evaluation of molecular screening for Lynch syndrome in patients with endometrial cancer ≤70 years. Gynecologic Oncology, 125(2), 414-420. doi: 10.1016/j.ygyno.2012. 01.049.
34. Lu, K. H.; Schorge, J. O.; Rodabaugh, K. J.; Daniels, M. S.; Sun, C. C.; Soliman, P. T.; et al. (2007). Prospective determination of prevalence of lynch syndrome in young women with endometrial cancer. Journal of Clinical Oncology, 25(33), 5158-5164. doi: 10.1200/JCO.2007.10.8597.
35. Lynch, H. T. (1999). Hereditary nonpolyposis colorectal cancer (HNPCC). Cytogenetics and Cell Genetics, 86(2), 130-135.
36. Mvundura, M.; Grosse, S. D.; Hampel, H.; & Palomaki, G. E. (2010). The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer. Genetics in Medicine, 12(2), 93-104. doi: 10.1097/GIM.0b013e3181cd666c.
37. Palomaki, G. E.; McClain, M. R.; Melillo, S.; Hampel, H. L.; & Thibodeau, S. N. (2009). EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genetics in Medicine, 11(1), 42-65.
38. Pappa, K. I.; Choleza, M.; Markaki, S.; Giannikaki, E.; Kyroudi, A.; Vlachos, G.; et al. (2006). Consistent absence of BRAF mutations in cervical and endometrial cancer despite KRAS mutation status. Gynecologic Oncology, 100(3), 596-600. doi: 10.1016/j.ygyno.2005.09.029.
39. Peres, J. (2010). To screen or not to screen for Lynch syndrome. Journal of the National Cancer Institute, 102(18), 1382-1384.
40. Pinol, V.; Castells, A.; Andreu, M.; Castellvi-Bel, S.; Alenda, C.; Llor, X.; et al. (2005). Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. Journal of the American Medical Association, 293(16), 1986-1994. doi: 10.1001/jama.293.16.1986.
41. Ramsoekh, D.; Wagner, A.; van Leerdam, M.; Dooijes, D.; Tops, C.; Steyerberg, E.; et al. (2009). Cancer risk in MLH1, MSH2 and MSH6 mutation carriers; different risk profiles may influence clinical management. Hereditary Cancer in Clinical Practice, 7(1), 17.
42. Resnick, K.; Straughn, J. M.; Jr.; Backes, F.; Hampel, H.; Matthews, K. S.; & Cohn, D. E. (2009a). Lynch syndrome screening strategies among newly diagnosed endometrial cancer patients. Obstetrics and Gynecology, 114(3), 530-536. doi: 10.1097/AOG.0b013e3181b11ecc00006250-200909000-00008.
43. Resnick, K. E.; Hampel, H.; Fishel, R.; & Cohn, D. E. (2009b). Current and emerging trends in Lynch syndrome identification in women with endometrial cancer. Gynecologic Oncology, 114(1), 128-134. doi: 10.1016/j.ygyno.2009.03.003.
44. Risinger, J. I.; Berchuck, A.; Kohler, M. F.; Watson, P.; Lynch, H. T.; & Boyd, J. (1993). Genetic instability of microsatellites in endometrial carcinoma. Cancer Research, 53(21), 5100-5103.
45. Salvesen, H. B.; Kumar, R.; Stefansson, I.; Angelini, S.; MacDonald, N.; Smeds, J.; et al. (2005). Low frequency of BRAF and CDKN2A mutations in endometrial cancer. International Journal of Cancer, 115(6), 930-934. doi: 10.1002/ijc.20702.
46. Schmeler, K. M.; Lynch, H. T.; Chen, L. M.; Munsell, M. F.; Soliman, P. T.; Clark, M. B.; et al. (2006). Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. The New England Journal of Medicine, 354(3), 261-269. doi: 10.1056/NEJMoa052627.
47. Senter, L.; Clendenning, M.; Sotamaa, K.; Hampel, H.; Green, J.; Potter, J. D.; et al. (2008). The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. Gastroenterology, 135(2), 419-428. doi: 10.1053/j.gastro.2008. 04.026.
48. Shia, J. (2008). Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry. Journal of Molecular Diagnostics, 10(4), 293-300. doi: 10.2353/jmoldx.2008.080031.
49. Shia, J.; Stadler, Z.; Weiser, M. R.; Rentz, M.; Gonen, M.; Tang, L. H.; et al. (2011). Immunohistochemical staining for DNA mismatch repair proteins in intestinal tract carcinoma: how reliable are biopsy samples? The American Journal of Surgical Pathology, 35(3), 447-454. doi: 10.1097/PAS. 0b013e31820a091d.
50. Sinicrope, F. A.; & Sargent, D. J. (2009). Clinical implications of microsatellite instability in sporadic colon cancers. Current Opinion in Oncology, 21(4), 369-373. doi: 10.1097/CCO.0b013e32832c94bd.
51. Sjursen, W.; Haukanes, B. I.; Grindedal, E. M.; Aarset, H.; Stormorken, A.; Engebretsen, L. F.; et al. (2010). Current clinical criteria for Lynch syndrome are not sensitive enough to identify MSH6 mutation carriers. Journal of Medical Genetics, 47(9), 579-585. doi: 10.1136/jmg.2010.077677.
52. Stoffel, E.; Mukherjee, B.; Raymond, V. M.; Tayob, N.; Kastrinos, F.; Sparr, J.; et al. (2009). Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. Gastroenterology, 137(5), 1621-1627. doi: 10.1053/j.gastro.2009.07.039.
53. Stormorken, A. T.; Clark, N.; Grindedal, E.; Maehle, L.; & Moller, P. (2007). Prevention of colorectal cancer by colonoscopic surveillance in families with hereditary colorectal cancer. Scandinavian Journal of Gastroenterology, 42(5), 611-617. doi: 10.1080/00365520601010230.
54. Stupart, D. A.; Goldberg, P. A.; Algar, U.; & Ramesar, R. (2009). Surveillance colonoscopy improves survival in a cohort of subjects with a single mismatch repair gene mutation. Colorectal Disease, 11(2), 126-130. doi: 10.1111/j.1463-1318.2008.01702.x.
55. Umar, A.; Boland, C. R.; Terdiman, J. P.; Syngal, S.; de la Chapelle, A.; Rüschoff, J.; et al. (2004). Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. Journal of the National Cancer Institute, 96(4), 261-268. doi: 10.1093/jnci/djh034.
56. Vasen, H.; Mecklin, J. P.; Khan, P. M.; & Lynch, H. T. (1991). The international collaborative group on hereditary non-polyposis colorectal cancer (ICG-HNPCC). Diseases of the Colon & Rectum, 34(5), 424-425.
57. Vasen, H.; Watson, P.; Mecklin, J. P.; & Lynch, H. T. (1999). New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology, 116(6), 1453-1456.
58. Weissman, S.; Burt, R.; Church, J.; Erdman, S.; Hampel, H.; Holter, S.; et al. (2012). Identification of individuals at risk for Lynch syndrome using targeted evaluations and genetic testing: National Society of Genetic Counselors and the Collaborative group of the Americas on Inherited Colorectal Cancer Joint Practice Guideline. Journal of Genetic Counseling, 21(4), 484-493. doi: 10.1007/s10897-011-9465-7.
59. Williams, J.; & Williams, M. (2011). Informed consent and immunohistochemistry screening for Lynch syndrome. Genetics in Medicine, 13(9), 848-849.
60. Zhang, L. (2008). Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part II. The utility of microsatellite instability testing. Journal of Molecular Diagnostics, 10(4), 301-307. doi: 10.2353/jmoldx.2008.080062.